| Size | Price | Stock | Qty |
|---|---|---|---|
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
NPC1L1; Nrf2
Ezetimibe ketone targets the same cholesterol absorption pathway as its parent drug. Ezetimibe is a selective inhibitor of cholesterol absorption in the gut. Ezetimibe ketone is a phase-I metabolite that may contribute to the overall pharmacological profile and metabolism of the parent drug. |
|---|---|
| ln Vitro |
In vitro, Ezetimibe ketone is characterized as a phase-I metabolite of Ezetimibe. It has antioxidant activity. The compound is used as a reference standard for analytical method development and quality control applications.
|
| ln Vivo |
In vivo, Ezetimibe ketone is formed as a phase-I metabolite following Ezetimibe administration. It is a major metabolite in humans and contributes to the overall pharmacokinetic profile of the parent drug. The compound is used as a reference standard for the quantification of Ezetimibe and its metabolites in biological samples.
|
| Enzyme Assay |
In vitro assays for Ezetimibe ketone typically involve analytical method development using HPLC or LC-MS. The compound is used as a reference standard to identify and quantify the metabolite in Ezetimibe samples. Its retention time and mass spectrum are characterized for method validation.
|
| Cell Assay |
For in vitro cell-based assays, Ezetimibe ketone is not typically used, as it is a metabolite and not a pharmacological agent. It could be used to study its potential effects on cholesterol absorption if necessary, but its primary role is as an analytical reference standard.
|
| Animal Protocol |
In vivo animal studies with Ezetimibe ketone are not typically performed, as it is a metabolite and not a therapeutic candidate. Its use is confined to analytical and pharmacokinetic studies. The compound is used as a reference standard for the quantification of Ezetimibe and its metabolites in biological samples.
|
| ADME/Pharmacokinetics |
Ezetimibe ketone (CAS: 191330-56-0) has a molecular weight of 407.40 g/mol and a molecular formula of C24H19F2NO3. Chemical name: (3R,4S)-1-(4-Fluorophenyl)-3-(3-(4-fluorophenyl)-3-oxopropyl)-4-(4-hydroxyphenyl)azetidin-2-one. Appearance: white to off-white solid. Purity: ≥98%. Storage: -20°C.
|
| Toxicity/Toxicokinetics |
Ezetimibe ketone is a research compound and is not approved for human therapeutic use. As a metabolite standard, it is used in very small quantities and does not pose significant toxicity risks under normal handling. Standard laboratory safety precautions should be followed when handling the compound.
|
| References |
|
| Additional Infomation |
Ezetimibe ketone (EZM-K) is a phase-I metabolite of Ezetimibe, a selective inhibitor of cholesterol absorption in the gut. It has antioxidant activity. It has a molecular weight of 407.40 g/mol and a molecular formula of C24H19F2NO3. It is not FDA-approved and is intended for research use only.
|
| Molecular Formula |
C24H19NO3
|
|---|---|
| Molecular Weight |
407.40936
|
| Exact Mass |
407.133
|
| Elemental Analysis |
C, 70.75; H, 4.70; F, 9.33; N, 3.44; O, 11.78
|
| CAS # |
191330-56-0
|
| Related CAS # |
191330-56-0
|
| PubChem CID |
9801494
|
| Appearance |
White to off-white solid powder
|
| Density |
1.325
|
| Boiling Point |
656.1±55.0 °C at 760 mmHg
|
| Flash Point |
350.6±31.5 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.615
|
| LogP |
3.79
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
30
|
| Complexity |
606
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1=C(C=CC(=C1)F)C(=O)CC[C@@H]2[C@@H](C3=CC=C(C=C3)O)N(C4=CC=C(C=C4)F)C2=O
|
| InChi Key |
UEPZDXMEEKCJSP-FYYLOGMGSA-N
|
| InChi Code |
InChI=1S/C24H19F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21,23,28H,13-14H2/t21-,23-/m1/s1
|
| Chemical Name |
(3R,4S)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-oxopropyl]-4-(4-hydroxyphenyl)azetidin-2-one
|
| Synonyms |
Ezetimibe ketone; EZM K; EZM-K
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~245.5 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.07 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.25 mg/mL (3.07 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (3.07 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4545 mL | 12.2726 mL | 24.5453 mL | |
| 5 mM | 0.4909 mL | 2.4545 mL | 4.9091 mL | |
| 10 mM | 0.2455 mL | 1.2273 mL | 2.4545 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
